Core Viewpoint - The company, Shandong Boyuan Pharmaceutical Chemical Co., Ltd., is engaged in the research, production, and sales of fine chemicals, with a focus on iodine compounds and precious metal catalysts, showing a mixed financial performance in recent periods [2]. Group 1: Company Overview - Shandong Boyuan Pharmaceutical Chemical Co., Ltd. was established on August 6, 2008, and is located in Shouguang City, Shandong Province [2]. - The company specializes in fine chemical products, including organic and inorganic iodides, precious metal catalysts, luminescent materials, and hexamethyldisilazane [2]. - The revenue composition of the company includes iodides (74.56%), specialty functional chemicals (12.79%), trading business (9.94%), and others (2.72%) [2]. Group 2: Financial Performance - For the first half of 2025, the company achieved a revenue of 747 million yuan, representing a year-on-year growth of 7.39% [2]. - The net profit attributable to the parent company was 99.04 million yuan, which reflects a year-on-year decrease of 19.09% [2]. - As of September 19, the number of shareholders increased to 10,300, with an average of 3,233 circulating shares per person, a decrease of 1.00% from the previous period [2]. Group 3: Market Activity - On September 22, the company's stock rose by 1.41%, with a trading volume of 284 million yuan [1]. - The financing buy-in amount for the company on the same day was 23.83 million yuan, while the financing repayment was 36.46 million yuan, resulting in a net financing buy-in of -12.63 million yuan [1]. - The total margin trading balance for the company as of September 22 was 113 million yuan, accounting for 4.39% of the circulating market value [1].
博苑股份9月22日获融资买入2382.65万元，融资余额1.13亿元